Fehr Gordon J. 4
4 · MERRIMACK PHARMACEUTICALS INC · Filed Apr 5, 2012
Insider Transaction Report
Form 4
Fehr Gordon J.
Director
Transactions
- Conversion
Common Stock
2012-04-03+22,222→ 164,681 total - Conversion
Series E Convertible Preferred Stock
2012-04-03−22,222→ 0 total→ Common Stock (22,222 underlying) - Purchase
Common Stock
2012-04-03$7.00/sh+1,428$9,996→ 142,459 total
Footnotes (1)
- [F1]Each share of Series E Convertible Preferred Stock automatically converted into one share of Common Stock upon the closing of the issuer's initial public offering and had no expiration date.